Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan;39(1):e70070.
doi: 10.1111/ctr.70070.

Amyloidosis and Heart Transplantation in a New Era

Melissa A Lyle  1 , Juan Maria M Farina  2 , Erin Wiedmeier-Nutor  3 , Vanda Lindpere  4 , Molly Klanderman  4 , Jose N Nativi-Nicolau  1 , Juan Carlos Leoni Moreno  1 , Rohan M Goswami  1 , Daniel S Yip  1 , Parag C Patel  1 , Taimur Sher  5 , Andrew N Rosenbaum  6 , Omar F AbouEzzeddine  6 , Barry A Boilson  6 , Sudhir S Kushwaha  6 , Alfredo L Clavell  6 , David E Steidley  2 , Brian W Hardaway  2 , Robert L Scott  2 , Lisa M LeMond  2 , Rafael Fonseca  3 , Morie A Gertz  7 , Angela Dispenzieri  7 , Martha Grogan  6 , Julie L Rosenthal  2
Affiliations

Amyloidosis and Heart Transplantation in a New Era

Melissa A Lyle et al. Clin Transplant. 2025 Jan.

Abstract

Background: The prognosis in patients with advanced cardiac amyloidosis (CA) remains poor.

Objectives: We sought to describe survival post heart transplantation (HT) in amyloid compared with non-amyloid recipients, highlight waitlist times within the new allocation system across three Organ Procurement and Transplantation Network (OPTN) regions, and describe multiorgan transplantation (MOT) in hereditary amyloidosis.

Methods: This is a retrospective review of end-stage CA patients who underwent HT at Mayo Clinic from January 2007 to December 2020. Wait time was compared in the new versus old OPTN allocation era starting December 18, 2018 by Wilcoxon rank sum test. All-cause mortality for those with and without CA was compared using Kaplan-Meier estimates with log rank analysis, censoring December 16, 2022.

Results: Fifty-five patients with CA underwent HT between 2007 and 2020, 8 light chain amyloidosis (AL) (14.5%), 28 hereditary transthyretin (ATTRv) (50.9%), 17 wildtype transthyretin (ATTRwt) (30.9%), and 2 hereditary apolipoprotein A1 (AApoA1) amyloidosis patients (3.6%). No significant difference in overall survival post-transplant was seen in amyloid compared with non-amyloid (p = 0.816). Median time to HT was shorter in the new system, 45 days (IQR 24, 78) versus 174 days (IQR 76.5, 483.5), p = 0.006. There was a decline in MOT in hereditary amyloidosis over time with the concomitant rise in disease-targeted therapies.

Conclusions: HT survival in CA patients was similar to non-amyloid patients. The new allocation system benefits this cohort with shorter wait times. There is less MOT in hereditary amyloidosis with increased utilization of disease-targeted therapy.

Keywords: cardiac amyloidosis; heart transplantation; multiorgan transplantation; survival.

PubMed Disclaimer

References

    1. M. A. Gertz, “Immunoglobulin Light Chain Amyloidosis: 2018 Update on Diagnosis, Prognosis, and Treatment,” American Journal of Hematology 93 (2018): 1169–1180.
    1. J. N. Buxbaum, A. Dispenzieri, D. S. Eisenberg, et al., “Amyloid Nomenclature 2022: Update, Novel Proteins, and Recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee,” Amyloid 29 (2022): 213–219.
    1. F. L. Ruberg, M. Grogan, M. Hanna, J. W. Kelly, and M. S. Maurer, “Transthyretin Amyloid Cardiomyopathy: JACC State‐of‐the‐Art Review,” Journal of the American College of Cardiology 73 (2019): 2872–2891.
    1. J. R. Mikhael, S. R. Schuster, V. H. Jimenez‐Zepeda, et al., “Cyclophosphamide‐Bortezomib‐Dexamethasone (CyBorD) Produces Rapid and Complete Hematologic Response in Patients With AL Amyloidosis,” Blood 119 (2012): 4391–4394.
    1. E. Kastritis, G. Palladini, M. C. Minnema, et al., “Daratumumab‐Based Treatment for Immunoglobulin Light‐Chain Amyloidosis,” New England Journal of Medicine 385 (2021): 46–58.